|
Region of interest
|
2TCM BPND (V
T-based)
|
SRTM BPND
|
|---|
|
Control
|
Raclopride
|
Control
|
Raclopride
|
|---|
|
Striatum
|
0.56 ± 0.05
|
0.41 ± 0.05 (−27%)*
|
0.51 ± 0.02
|
0.38 ± 0.05 (−26%)**
|
|
Hippocampus
|
0.30 ± 0.07
|
0.26 ± 0.06 (−13%)
|
0.26 ± 0.04
|
0.23 ± 0.05 (−13%)
|
|
Thalamus
|
0.33 ± 0.02
|
0.30 ± 0.01 (−10%)*
|
0.28 ± 0.06
|
0.26 ± 0.02 (−7%)
|
|
Hypothalamus
|
0.22 ± 0.03
|
0.18 ± 0.06 (−19%)
|
0.21 ± 0.03
|
0.16 ± 0.04 (−23%)
|
|
Cortex
|
0.13 ± 0.04
|
0.10 ± 0.02 (−27%)
|
0.11 ± 0.03
|
0.08 ± 0.02 (−24%)
|
|
Brainstem
|
0.22 ± 0.02
|
0.10 ± 0.02 (−53%)**
|
0.18 ± 0.04
|
0.07 ± 0.03 (−60%)**
|
|
Olfactory bulbs
|
0.08 ± 0.13
|
0.01 ± 0.04 (−88%)
|
0.10 ± 0.13
|
0.11 ± 0.05 (+10%)
|
|
Pituitary
|
0.36 ± 0.07
|
0.13 ± 0.04 (−23%)
|
0.71 ± 0.32
|
0.55 ± 0.53 (−22%)
|
- Data are presented as means ± SD, n = 4 for the control group and n = 3 for the raclopride-treated group (except for the SRTM BPND values, where n = 4). Next to the BPND values of the raclopride-treated group, percentage of change relative to the control group is shown
- *p < 0.05; **p < 0.01, 2-sided Welch test
